First Commercial Implants of Sequana Medical Products

Sequana Medical, the Medical University of Vienna and Vienna General Hospital (AKH Wien) reported that the first two commercial implants worldwide of the ALFApump System were performed at Vienna General Hospital in October. The ALFApump System is indicated for the management of refractory and recurrent ascites due to liver cirrhosis, a condition where massive and uncontrolled fluid accumulation occurs in the abdominal cavity.

“I believe that the ALFApump System represents a real breakthrough in the treatment of refractory ascites. By using the ALFApump, the patient no longer has to return to the hospital on a frequent basis to undergo drainage procedures. This positively impacts on both Quality of Life of the patient and the financial burden to the healthcare system. The implant procedure for both patients went smoothly and without complications”, commented Professor Peck-Radosavljevic. He is Vice-Chairman, Division of Gastroenterology and Hepatology, Dept. of Internal Medicine III, Vienna General Hospital.

The ALFApump System consists of a subcutaneously implanted battery-powered pump with a catheter placed in the abdominal cavity and another catheter connected to the bladder. The ALFApump System automatically and continually collects fluid as it forms in the abdominal cavity and moves it to the bladder, where it is eliminated through normal urination. The ALFApump is recharged wirelessly and can be programmed to meet the unique needs of each patient.